What is the purpose of this fund lending?

To provide working capital for the U.S. subsidiary’s acquisition of CDMO operating assets in Maryland.

NT$2,573,770 thousand (approximately NT$2.57 billion).

Is there any collateral?

No collateral has been provided; this is an unsecured loan.

What are the repayment terms?

Full repayment of principal and interest within one year at 5.2% annual interest.

What percentage of consolidated net equity does this represent?

17.67%, classified as a significant financial transaction.

AI News NQ Analysis

[Bora] Subsidiary Bora Global Ltd. Announces Fund Lending to Bora Pharmaceuticals USA Inc. under Public Company Fund Lending and Guarantee Regulations

NQ Score 77/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Bora Global Ltd., a subsidiary of Bora, has provided a loan of NT$2.57 billion to its U.S. subsidiary Bora Pharmaceuticals USA Inc. to support operational funding for the acquisition of CDMO operating assets in Maryland.

AI Analysis

Frequently Asked Questions

Q: What is the purpose of this fund lending?: A: To provide working capital for the U.S. subsidiary’s acquisition of CDMO operating assets in Maryland.
Q: How much was lent?: A: NT$2,573,770 thousand (approximately NT$2.57 billion).
Q: Is there any collateral?: A: No collateral has been provided; this is an unsecured loan.
Q: What are the repayment terms?: A: Full repayment of principal and interest within one year at 5.2% annual interest.
Q: What percentage of consolidated net equity does this represent?: A: 17.67%, classified as a significant financial transaction.